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Insulin-stimulated phosphorylation of protein
phosphatase 1 regulatory subunit 12B revealed
by HPLC-ESI-MS/MS
Kimberly Pham1†, Paul Langlais1†, Xiangmin Zhang1,2†, Alex Chao1, Morgan Zingsheim1 and Zhengping Yi1,2*
Abstract
Background: Protein phosphatase 1 (PP1) is one of the major phosphatases responsible for protein
dephosphorylation in eukaryotes. Protein phosphatase 1 regulatory subunit 12B (PPP1R12B), one of the regulatory
subunits of PP1, can bind to PP1cδ, one of the catalytic subunits of PP1, and modulate the specificity and activity of
PP1cδ against its substrates. Phosphorylation of PPP1R12B on threonine 646 by Rho kinase inhibits the activity of
the PP1c-PPP1R12B complex. However, it is not currently known whether PPP1R12B phosphorylation at threonine
646 and other sites is regulated by insulin. We set out to identify phosphorylation sites in PPP1R12B and to quantify
the effect of insulin on PPP1R12B phosphorylation by using high-performance liquid chromatography-electrospray
ionization-tandem mass spectrometry.
Results: 14 PPP1R12B phosphorylation sites were identified, 7 of which were previously unreported. Potential
kinases were predicted for these sites. Furthermore, relative quantification of PPP1R12B phosphorylation sites for
basal and insulin-treated samples was obtained by using peak area-based label-free mass spectrometry of fragment
ions. The results indicate that insulin stimulates the phosphorylation of PPP1R12B significantly at serine 29
(3.02 ± 0.94 fold), serine 504 (11.67 ± 3.33 fold), and serine 645/threonine 646 (2.34 ± 0.58 fold).
Conclusion: PPP1R12B was identified as a phosphatase subunit that undergoes insulin-stimulated phosphorylation,
suggesting that PPP1R12B might play a role in insulin signaling. This study also identified novel targets for future
investigation of the regulation of PPP1R12B not only in insulin signaling in cell models, animal models, and in
humans, but also in other signaling pathways.
Keywords: PPP1R12B, Phosphorylation, HPLC-ESI-MS/MS, Insulin signaling, Label-free, Quantification
Introduction
Protein phosphatase 1 (PP1) is one of the most abundant
serine/threonine phosphatases; it is responsible for most
protein dephosphorylation [1-3], which regulates diverse
biological processes in eukaryotes. Interactions between
catalytic subunits of PP1 (PP1c) and the regulatory subu-
nits of PP1 (PP1R) lead to the formation of numerous
PP1 complexes that have unique substrate specificities,
distinct subcellular localizations, and various regulatory
mechanisms [1-3].
Protein phosphatase 1 regulatory subunit 12B
(PPP1R12B), also known as myosin phosphatase target
subunit 2 (MYPT2), is one of the regulatory subunits of
PP1 and is predominantly expressed in cardiac/skeletal
muscle and brain [4,5]. PPP1R12B regulates muscle con-
traction, cardiac torsion, and sarcomere organization as
well as other cellular processes [5]. PPP1R12B contains
an RVxF binding motif (residues 53–56), several ankyrin
repeats, and a C-terminal leucine zipper domain, all of
which are involved in protein-protein interactions [4-7].
In addition, PPP1R12B has 108 serine, 63 threonine, and
16 tyrosine residues, 26 of which have been reported as
phosphorylated in the four large phosphorylation data-
bases (www.phosphosite.org, phospho.elm.eu.org, www.
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uniprot.org, and www.phosida.com). However, only
phosphorylation at threonine 646 (Thr646) has been
shown to regulate PPP1R12B function [5]. Thr646 was
phosphorylated by Rho-kinase in kidney COS7 cells, re-
ducing the activity of the PPP1R12B-PP1cδ complex [5].
Whether Thr646 phosphorylation plays the same inhibi-
tory role in PPP1R12B-PP1cδ complex activity in other
cells remains to be determined.
Insulin is a potent anabolic hormone that modulates a
wide variety of biological processes. Protein phosphoryl-
ation plays a critical role in relaying the insulin signal
from initiation at the insulin receptor to the transport of
GLUT4 to the plasma membrane. Dysregulated protein
phosphorylation events in insulin signaling may contrib-
ute to various diseases, such as type 2 diabetes and car-
diovascular diseases. Extensive research has been carried
out to study the role of kinases in insulin action. How-
ever, a mechanism for serine/threonine phosphatase ac-
tion in insulin signal transduction is largely unknown. In
an effort to discover phosphatases that may be involved
in insulin signaling, we identified protein phosphatase 1
regulatory subunit 12A (PPP1R12A) as a novel endogen-
ous, insulin stimulated interaction partner of insulin re-
ceptor substrate-1 (IRS-1), a well recognized player in
insulin signaling, implying that PPP1R12A might play a
role in IRS-1 dephosphorylation and insulin signaling
[8]. PPP1R12A is an isoform of PPP1R12B with high
expression in smooth muscle cells [9]. As mentioned
previously, PPP1R12B is predominantly expressed in car-
diac/skeletal muscle and brain. Thus, it is possible that
PPP1R12B could anchor the catalytic subunit of PP1,
PP1cδ, to dephosphorylate IRS-1 in cardiac/skeletal
muscle and brain. More recently, we provided a relative
global picture of PPP1R12A phosphorylation in CHO/IR
cells, and reported that insulin stimulated or suppressed
PPP1R12A phosphorylation at multiple sites [10]. It is
currently not known whether insulin plays a regulatory
role in PPP1R12B phosphorylation. Therefore, in the
present study, we used multi-segment high performance
liquid chromatography-electrospray ionization-tandem
mass spectrometry (HPLC-ESI-MS/MS) to identify and
quantify PPP1R12B phosphorylation sites that are regu-
lated by insulin. We utilized the peak area of MS2 gener-
ated fragment ions, an approach developed in our
laboratory [11], to quantify relative changes in PPP1R12B
phosphorylation after insulin treatment.
Results
We hypothesized that insulin would regulate phosphor-
ylation of PPP1R12B in Chinese hamster ovary cells
overexpressing human insulin receptor (CHO/IR).
Therefore we set out to identify PPP1R12B phosphoryl-
ation sites and assess how they respond to insulin. To
that end, overexpressed FLAG-tagged PPP1R12B was
isolated from CHO/IR cells by immunoprecipitation,
and then HPLC-ESI-MS/MS was performed, as
described in the Methods section. The spectra obtained
by HPLC-ESI-MS/MS confirmed the presence of
PPP1R12B with 63% sequence coverage (Figure 1).
Table 1 lists the PPP1R12B phosphopeptides detected by
HPLC-ESI-MS/MS and their respective predominant
phosphorylation sites. In all, 14 phosphorylation sites
were detected, 7 of which were previously not reported
as phosphorylation sites in the four large phosphoryl-
ation databases, and thus appear to be novel. These
novel, previously unknown phosphorylation sites include
Figure 1 Combined coverage map of peptides detected in tryptic digests of PPP1R12B expressed in CHO/IR cells using HPLC-ESI-MS/
MS analysis. 63% PPP1R12B sequence coverage was obtained from the 6 basal and 6 insulin samples as well as several preliminary experiments
for PPP1R12B peptide discovery. Detected peptides are highlighted in yellow; methionine oxidation sites are lowercase; serine/threonine
phosphorylation sites are highlighted in green; and novel phosphorylation sites are in boldface type.
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Thr31, Ser67, Ser711, Ser760, Ser762, Ser847, and
Ser849. Phosphorylation of PPP1R12B at Thr646,
observed in kidney cells by Okamoto et al. [5], was con-
firmed in CHO/IR cells; however, based on the tandem
mass spectra, the peptide containing phosphorylated
Thr646 might also be phosphorylated at Ser645 [12,13].
We confirmed the phosphorylation of PPP1R12B at
Ser29 [14], Ser445 [14], Ser504 [14], Ser506 [15], Ser839
[14,16], and Ser947 [14,17]. The MS/MS spectra for the
peptides containing phosphorylated Ser645/Thr646 and
Ser760 are shown in Additional file 1: Figure S1 and
Figure S2. We have posted the Scaffold file on http://
cphs-web.cphs.wayne.edu/zyi/PPP1R12B so that readers
can access all MS/MS spectra after installation of the
Scaffold viewer, which is freely available on http://www.
proteomesoftware.com.
To assess the effect of insulin on PPP1R12B phosphor-
ylation, serum-starved, CHO/IR cells overexpressing
FLAG-tagged PPP1R12B were either left untreated or
treated with insulin. FLAG-tagged PPP1R12B was
immunoprecipitated and resolved by 10% SDS-PAGE.
Coomassie blue stain was used to visualize the protein
(Additional file 1: Figure S3), after which the gel area
corresponding to PPP1R12B was excised and subjected
to trypsin digestion. Relative quantification of phosphor-
ylation by HPLC-ESI-MS/MS was performed as
described in the Methods section. Six independent bio-
logical replicates (6 control and 6 insulin-treated, total
12 samples) were utilized to increase the confidence of
our findings. The control and insulin-stimulated samples
that were harvested on the same day, resolved on the
same gel, and analyzed by HPLC-ESI-MS/MS during the
same period of time were paired to minimize day-to-day
variations. Eight nonphosphorylated PPP1R12B peptides
were used as endogenous internal standards to measure
total PPP1R12B present per sample (Table 2) and their
peak area and retention times are listed in Additional file
2: Table S1.
Analysis of PPP1R12B phosphorylation revealed that
several PPP1R12B phosphopeptides contain multiple
phosphorylation sites (Table 1). To quantify the phos-
phorylated peptides, we generated MS2 fragment ions
and used the peak areas of the fragment b and y ions
(Table 3), as described by Langlais et al. [11]. Among
the 14 phosphorylation sites identified, we obtained
quantitative information for 6 of them (Figure 2 and
Table 4). Please note that even though we performed 6
independent comparisons between basal and insulin
treated conditions, 2 of the comparisons had a relatively
larger deviation from the other 4 comparisons. There-
fore, they were excluded from Figure 2 and Table 4.
Nonetheless, biological findings regarding insulin stimu-
lation for 6 comparisons are the same as those for 4
comparisons. Each PPP1R12B phosphorylation site was
normalized by the average value of the respective control
sample and then expressed as fold change over control
Table 1 PPP1R12B phosphopeptides and predicted potential kinases
Start Stop Peptide sequence Phosphorylation site Predicted kinases*
28 38 GpSLTEQEPAER Ser29† CK2α, CK2α’, DMPK, PAK-1, PAK-2, PAK-3, PAK-4, PKAα, PKAβ, p70-S6K
GSLpTEQEPAER Thr31{ CK2α, CK2α’
54 76 VRFEDGAVFLAACpSSGDTDEVRK Ser67 CK2α, CK2α’
445 458 pTGSHNMLSEVANSR Thr445 DMPK, NEK2
501 511 KLNpSTSDIEEK Ser504† CK2α, CK2α’
KLNSTpSDIEEK Ser506 CK2α, CK2α’
645 659 pSpTQGVTLTDLQEAER Ser645/Thr646† AIM1, PAK-1, PAK-2, PAK-3, PKAα, PKAβ, DMPK, Pim-2h/ DMPK, Pim-2h, RhoK
711 720 pSLDEEPICHR Ser711 CK2α, CK2α’
755 773 FSVPDpSESSETTTNTTTAK Ser760 CK2α, CK2α’
FSVPDSEpSSETTTNTTTAK Ser762 CK2α, CK2α’, TLK1
837 853 LEpSGGSNPTTSDSYGDR Ser839 ActRIIA, ActRIIB, CLK1, CLK2, DMPK, RAGE-1, TGFR-2
LESGGSNPTTpSDSYGDR Ser847 CK2α, CK2α’
LESGGSNPTTSDpSYGDR Ser849 ActRIIA, ActRIIB, TGFR-2
945 954 KMpSEMEEEMK Ser947 CK2α, CK2α’
* Using NetworKIN 2.0 Beta (http://networkin.info/version_2_0/newPrediction.php) as well as literature searches.
† Insulin-stimulated sites.
{ Novel phosphorylation sites are indicated in boldface type.
Kinase abbreviations: CK2α, casein kinase II, alpha chain; CK2α’, casein kinase II, alpha' chain; DMPK, myotonic dystrophy protein kinase; PAK-1, p21-activated
kinase 1; PAK-2, p21-activated kinase 2; PAK-3, p21-activated kinase 3; PAK-4, p21-activated kinase 4; PKAα, cAMP-dependent protein kinase, alpha-catalytic
subunit; PKAβ, cAMP-dependent protein kinase, beta-catalytic subunit; p70-S6K, ribosomal protein S6 kinase 1; NEK2, nimA-related protein kinase 2; AIM-1, Aurora-
and Ipl1-like midbody-associated protein 1; Pim-2h, serine/threonine-protein kinase Pim-2; RhoK, Rho kinase, TLK1, tousled-like kinase 1; ACTRIIA, activin receptor
type II precursor; ACTRIIB, activin receptor type IIB precursor; CLK1, CDC-like kinase 1; CLK2, CDC-like kinase 2; RAGE-1, renal tumor antigen 1; TGFR-2, TGF-beta
receptor type II precursor.
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Table 2 PPP1R12B internal standard peptides
Start Stop Peptide sequence Molecular weight (Da) Quantified (m/z)*
282 303 LGQTPFDVADEGLVEHLELLQK 2451.2766 817.7637 (+3)
1226.1419 (+2)
327 333 IQSGFFK 826.4458 413.7265 (+2)
826.4458 (+1)
397 417 SSITEQIPAPAQNTFSASSAR 2163.0677 721.6941 (+3)
1082.0375 (+2)
492 500 SYISSLAPR 993.5364 497.2718 (+2)
993.5364 (+1)
515 522 ESAVNLVR 887.4945 444.2509 (+2)
887.4945 (+1)
741 754 PSLYTSSHLLWTNR 1674.8598 558.9581 (+3)
837.9336 (+2)
837 853 LESGGSNPTTSDSYGDR 1742.7464 871.8768 (+2)
966 975 LKDENGALIR 1128.6371 564.8222 (+2)
1128.6371 (+1)
* m/z, mass-to-charge ratio.
Combined peak areas for the +1, +2, and +3 (when detected) charge states for each peptide were obtained by integration of the appropriate reconstructed ion
chromatograms.
Table 3 Unique fragment ions used to quantify phosphorylation sites
Start Stop Peptide sequence Phosphorylation site Product ion (m/z)* Mass (Da)
28 38 GpSLTEQEPAER Ser29 y8 (+1) 959.40
y9 (+1) 1072.50
501 511 KLNpSTSDIEEK Ser504 b4 (+1) 523.23
y7 (+1) 821.39
645 659 pSpTQGVTLTDLQEAER Ser645/Thr646 b2 (+1) 269.05
b3 (+1) 397.11
b4 (+1) 454.13
b5 (+1) 553.20
y10 (+1) 1175.59
y11 (+1) 1274.66
y12 (+1) 1331.68
y13 (+1) 1459.74
711 720 pSLDEEPICHR Ser711 y6 (+1) 754.37
y7 (+1) 883.41
y8 (+1) 998.44
755 773 FSVPDpSESSETTTNTTTAK Ser760† b7 (+1) 842.30
y12 (+1) 1241.59
y13 (+1) 1370.63
837 853 LEpSGGSNPTTSDSYGDR Ser839 b3 (+1) 410.10
y12 (+1) 1299.50
y13 (+1) 1356.60
y14 (+1) 1413.60
* m/z, mass-to-charge ratio.
† Since Scaffold PTM analysis indicated that only Ser760 or Ser762 is phosphorylated on this peptide, unique fragment ion selection was based on the comparison
between pSer760 and pSer762.
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± SEM (n= 4). Phosphorylation of PPP1R12B at Ser711,
Ser760, and Ser839 was not significantly affected by in-
sulin (Figure 2 and Table 4). In contrast, significant insu-
lin stimulation was observed for the phosphorylation of
PPP1R12B at Ser29, Ser504, and Ser645/Thr646 (Figure 2
and Table 4). Unfortunately, we were unable to discern
between the isobaric peptides of aa645-659 that are
phosphorylated at either Ser645 or Thr646, as the re-
spective y14 and y15 ions were not readily detectable
(which explains why thus were not included in Table 3).
We have been forced to group the quantification of
these 2 phosphorylation sites together. After correcting
for sample loading by dividing the peak area for each
phosphopeptide by the corresponding mean peak area of
PPP1R12B representative peptides from each sample,
these three sites showed an increase in all 4 comparisons
after insulin treatment (P < 0.05). Phosphorylation
increased 3.02 ± 0.94 fold at Ser29, 11.67 ± 3.33 fold at
Ser504, and 2.34 ± 0.58 fold at Ser645/Thr646. The
increased phosphorylation of PPP1R12B after insulin
stimulation has not been previously reported for these
sites. We performed a literature search and also utilized
NetworKIN 2.0, an online bioinformatics tool, to predict
kinases capable of phosphorylating PPP1R12B (Table 1)
[18,19]. The potential kinases for the PPP1R12B
phosphorylation sites that underwent insulin stimulation
(i.e., Ser29, Ser504, and S695/Thr646) included p21-
activated kinases (PAKs), casein kinase II (CK2), myo-
tonic dystrophy protein kinase (DMPK), and Rho kinase,
all of which have been shown to be activated by insulin
[20-22]. Future studies will test the involvement of these
kinases in insulin-stimulated phosphorylation of PPP1R12B.
Discussion
It has been shown that phosphorylation of PPP1R12B at
Thr646 by Rho kinase reduces the activity of the
PPP1R12B-PP1cδ complex against smooth muscle my-
osin light chain in COS7 kidney cells [5]. Whether
Thr646 phosphorylation plays the same inhibitory role
in PPP1R12B-PP1cδ complex activity in CHO/IR cells
remains to be elucidated. A previous report indicated
that insulin might stimulate Rho kinase activity [23].
Thus, it is possible that after insulin stimulation, Rho
kinase phosphorylates Thr646 in PPP1R12B in CHO/IR
cells and serves as a negative regulator of the PPP1R12B-
PP1cδ complex. We also observed the phosphorylation of
PPP1R12B at the pThr646 proximal site, Ser645, although
these 2 phospho sites were not distinguishable based on
the MS/MS spectrum, and whether they behave similarly
in the regulation of PPP1R12B is unclear at present.
Figure 2 The effect of insulin on PPP1R12B phosphorylation. Immunoprecipitated FLAG-tagged PPP1R12B was resolved by 10% SDS-PAGE
and stained with Coomassie blue to visualize the protein. The gel area corresponding to PPP1R12B was excised and subjected to trypsin
digestion and HPLC-ESI-MS/MS analysis as described in the Methods section. Relative quantification of each phosphopeptide was obtained by
comparing normalized peak-area ratios against the average of 8 representative PPP1R12B peptides. Each PPP1R12B phosphorylation site was
normalized by the average value of the respective basal sample and then expressed as fold change over control (n = 4). Box and whisker plots of
the ratios were utilized to visualize the effect of insulin on PPP1R12B phosphorylation.
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Mutation of Thr646 or Ser645 to alanine is on-going to
assess the role of PPP1R12B phosphorylation on PP1c ac-
tivity and insulin signaling.
Ser29 and Thr31 are in close proximity to the PP1c
binding motif (K/R-I/V-X-F/W, residues 53–56 in
human PPP1R12B) [5]. In addition, the crystalline
structure of the PP1 complex between the chicken
PP1c δ isoform (also called β isoform) and amino acids
1–299 of protein phosphatase 1 regulatory subunit
12A (PPP1R12A) (also called MYPT1, an isoform of
PPP1R12B) has been resolved [24]. It indicates that
residues 1–34, which precede the PP1c binding motif
in human PPP1R12A (residues 35–38), also interact
with PP1cδ. It has been shown that a short peptide
(residues 23–38) of PPP1R12A, which contains the
PP1c binding motif but lacks the N terminus, binds to
PP1c but has no effect on PP1cδ catalytic activity [25],
whereas a peptide containing residues 1–38 of
PPP1R12A both interacts with PP1c and increases its
phosphatase activity. Hence, it is reasonable to con-
clude that some structure within residues 1–22 is re-
sponsible for the increased catalytic activity. To date,
structural information for PPP1R12B is lacking. How-
ever, based on the similarity between PPP1R12A and
PPP1R12B as well as the insulin-stimulated phosphor-
ylation of Ser29 (pS29), we speculate that pS29 might
play a role in regulating PP1cδ activity when it is in a
complex with PPP1R12B. Without pS29, PPP1R12B
might still bind to PP1cδ through the PP1c binding
motif; however, the resulting complex might not have
the full phosphatase activity against its substrates. We
are in the process of mutating Ser29 to alanine to test
Table 4 Effect of insulin on PPP1R12B phosphorylation,
n = 4
Ser29
Experiment Normalized peak area # Ratio †
Control Insulin Control Insulin
1 1.10E-05 3.89E-05 0.43 1.51
2 1.20E-05 6.84E-05 0.46 2.65
3 2.85E-05 5.64E-05 1.10 2.18
4 5.18E-05 1.48E-04 2.01 5.75
Average 2.58E-05 1.00 3.02*
SEM 0.37 0.94
Ser504
Experiment Normalized peak area # Ratio †
Control Insulin Control Insulin
1 2.12E-06 7.66E-05 0.22 8.06
2 2.53E-05 1.85E-04 2.66 19.45
3 1.06E-05 1.39E-04 1.11 14.62
4 0.00E + 00 4.33E-05 0.00 4.56
Average 9.51E-06 1.00 11.67*
SEM 0.60 3.33
Ser645/T646
Experiment Normalized peak area # Ratio †
Control Insulin Control Insulin
1 1.50E-04 3.00E-04 0.52 1.05
2 2.93E-04 5.89E-04 1.02 2.05
3 3.01E-04 7.03E-04 1.05 2.45
4 4.04E-04 1.10E-03 1.41 3.82
Average 2.87E-04 1.00 2.34*
SEM 0.18 0.58
Ser711
Experiment Normalized peak area # Ratio †
Basal Insulin Basal Insulin
1 4.15E-05 4.29E-05 0.56 0.58
2 5.58E-05 2.36E-05 0.76 0.32
3 7.55E-05 8.23E-05 1.02 1.12
4 1.22E-04 6.52E-05 1.66 0.88
Average 7.37E-05 1.00 0.73
SEM 0.24 0.17
Ser760
Experiment Normalized peak area # Ratio †
Basal Insulin Basal Insulin
1 3.43E-05 2.13E-05 1.00 0.62
2 3.59E-05 2.85E-05 1.04 0.83
3 2.84E-05 2.83E-05 0.83 0.82
4 3.89E-05 2.08E-05 1.13 0.60
Table 4 Effect of insulin on PPP1R12B phosphorylation,
n = 4 (Continued)
Average 3.44E-05 1.00 0.72
SEM 0.06 0.06
Ser839
Experiment Normalized peak area # Ratio †
Basal Insulin Basal Insulin
1 1.36E-05 1.67E-05 0.16 0.20
2 2.74E-05 5.48E-05 0.33 0.66
3 3.23E-05 0.00E + 00 0.39 0.00
4 2.61E-04 2.70E-04 3.12 3.24
Average 8.36E-05 1.00 1.02
SEM 0.71 0.75
# Normalized peak area: obtained by dividing the peak area of a
phosphopeptide by the mean value of the peak area of the 8
unphosphorylated representative peptides of PPP1R12B.
† Ratio: obtained by dividing the normalized peak area for a phosphopeptide
in each experiment by the average of the normalized peak area under the
control condition.
* P< 0.05 compared with control.
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the functional consequence of this mutation, such as
effect on phosphatase activity.
Ser504 of PPP1R12B exhibited over 11-fold more
phosphorylation after insulin treatment. Because it was
found, by surface plasmon resonance, that PP1cδ might
interact with the PPP1R12A truncation containing resi-
dues 304–511 [25], we speculate that phosphorylation at
Ser504 might also be involved in the interplay between
PPP1R12B and PP1cδ. The increase in phosphorylation
of PPP1R12B at Ser504 represents the strongest fold
change of any insulin-stimulated serine or threonine
phosphorylation site that we have studied to date using
this mass spectrometry technique to quantify protein
phosphorylation [11,26-28]. The strength of the insulin-
stimulated PPP1R12B phosphorylation at Ser504 could
indicate that it is a major regulatory mechanism respon-
sible for controlling PPP1R12B function in insulin sig-
naling. Mutation of Ser504 to alanine is on-going to
assess the function of this phosphorylation site in regu-
lating PPP1R12B and PP1c activity.
Insulin signaling is crucial to many biological processes,
such as glycogen synthesis, glucose transport, mitogenesis,
and protein synthesis. The intracellular actions of insulin
are mediated by controlled protein phosphorylation and
dephosphorylation [29]. Insulin activates the insulin recep-
tor, and the activated insulin receptor then phosphorylates
tyrosine residues IRS-1, which allows IRS-1 to recruit phos-
phatidylinositide 3-kinase and leads to phosphorylation of
Akt on threonine/serine residues. Activated Akt phosphor-
ylates its substrate proteins, such as AS160, and promotes
GLUT4 translocation to the plasma membrane, leading to
enhanced glucose uptake. In addition, activated Akt can in-
crease glycogen synthesis by phosphorylating glycogen syn-
thase kinase 3, and decreasing the phosphorylation of
glycogen synthase. Moreover, phosphorylated Akt enhances
protein synthesis through serine/threonine phosphorylation
of mammalian target of rapamycin and ribosomal protein
S6 kinase beta-1 [29]. Furthermore, IRS-1 interacts with
growth factor receptor binding protein 2, leading to serine/
threonine phosphorylation of a number of signaling pro-
teins in the mitogen-activated protein kinase pathway and
subsequent promotion of cell survival and mitogenesis [30].
As discussed above, several of the serine/threonine kinases,
such as Akt, mammalian target of rapamycin, ribosomal
protein S6 kinase beta-1, glycogen synthase kinase 3, and
mitogen-activated protein kinase, have been shown to play
a role in insulin signaling. However, a mechanism for
serine/threonine phosphatase action in insulin signal trans-
duction is not known. The present study identified
PPP1R12B, a regulatory subunit of PP1 (which is a serine/
threonine protein phosphatase), as a new insulin-signaling
protein with site-specific phosphorylation that is regulated
by insulin in CHO/IR cells. The results presented in this
study will provide targets for future investigations delineat-
ing the role of serine/threonine phosphatases in insulin
signaling.
Conclusions
We analyzed the effect of insulin on PPP1R12B phos-
phorylation using HPLC-ESI-MS/MS and found that in-
sulin stimulated phosphorylation of Ser29, Ser504, and
Ser645/Thr646. We also identified 7 previously unre-
ported PPP1R12B phosphorylation sites, namely, Thr31,
Ser67, Ser711, Ser760, Ser762, Ser847, and Ser849. Al-
though these novel sites did not respond to insulin in
CHO/IR cells, they provide targets for investigating the
regulation of PPP1R12B and/or PP1cδ in other cells, such
as smooth muscle cells, cardiomyocytes, or COS7 kidney
cells. A summary of the PPP1R12B phosphorylation find-
ings is provided in Figure 3. It is noted that overexpression
of insulin receptor might lead to artifactual phosphoryl-
ation. Nonetheless, these results provide novel targets for
future investigation of the regulation of PPP1R12B not
only in insulin signaling in cell models, animal
Figure 3 Summary of PPP1R12B phosphorylation findings. The black bar preceding the Ankyrin repeats represents the PP1c binding motif,
amino acids 53–56. An asterisk (*) indicates sites with a significant increase in phosphorylation after insulin stimulation. Novel sites are indicated
in boldface type.
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models, and in humans, but also in other signaling path-
ways. Future experiments will confirm the effect of insulin
on PPP1R12B phosphorylation in both animal and human
muscle, while site-specific mutagenesis will be employed to
assess the role of PPP1R12B phosphorylation on PP1c ac-
tivity and insulin signaling within in vitro insulin-signaling
models, such as L6 myotubes.
Methods
Materials
The sequencing-grade trypsin and anti-FLAG antibody
were purchased from Sigma (St. Louis, MO), and the
C18 ZipTip from Millipore (Billerica, MA). Chinese
hamster ovary cells overexpressing the insulin receptor
(CHO/IR) were a gift from Dr. Feng Liu (University of
Texas Health Science Center at San Antonio, TX). Es-
tablishment of the CHO/IR cell line was described previ-
ously [31]. The cDNA encoding full-length wild-type
human PPP1R12B was a gift from Dr. Ryuji Okamoto
and Dr. Masaaki Ito (Mie University, Tsu, Mie, Japan).
Cell culture, transfection, immunoprecipitation, and
SDS-PAGE
CHO/IR cells were transfected with 5–10 μg of FLAG-
tagged PPP1R12B plasmid DNA using Lipofectamine re-
agent (Invitrogen, Carlsbad, CA), serum starved for 4 h
at 37°C, and left untreated or treated with insulin (100
nM) for 15 min at 37°C. The cells were lysed, and cell
lysates (1 mg) were diluted in lysis buffer and incubated
with 2 μg of anti-FLAG antibody for PPP1R12B purifica-
tion. The immunoprecipitates were collected with Pro-
tein A agarose beads (Sigma, St. Louis, MO). Samples
were boiled in sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) sample buffer and
resolved by 10% 1D-SDS-PAGE. The proteins were then
visualized by Coomassie blue staining (Sigma, St. Louis,
MO). Please see Additional file 3 for more details.
In-gel digestion and mass spectrometry
In-gel digestion and mass spectrometry were performed
as described previously [11,26,32]. Briefly, the gel por-
tions containing PPP1R12B were excised, destained,
dehydrated, dried, and subjected to trypsin digestion
overnight. The resulting peptides were desalted and ana-
lyzed by on-line HPLC on a linear trap quadrupole-
Fourier transform ion cyclotron resonance (LTQ-
FTICR). Please see the Additional file 3 for details.
Phosphorylation sites were located using Scaffold
PTM (version 1.0.3, Proteome Software, Portland, OR), a
program based on the Ascore algorithm [33,34]. Sites
with Ascores ≥ 13 (P ≤ 0.05) were considered confidently
localized [33,34].
Peak areas for each peptide were obtained by integrat-
ing the appropriate reconstructed ion chromatograms
with 10 ppm error tolerance for precursor-ion masses
acquired using FTICR and 0.5 Dalton for the fragment
ions acquired using the LTQ mass analyzer. Relative
quantification of each phosphopeptide was obtained by
comparing normalized peak-area ratios for control and
insulin-treated samples [11,26,32].
Statistical analysis
Statistical significance was assessed by comparing con-
trol and insulin-stimulated phosphopeptide peak areas
(normalized to PPP1R12B representative peptides as
described above) using the paired t-test.
Additional files
Additional file 1: Figure S1. Tandem mass spectrum of Ser645/Thr646
(ambiguous) phosphorylation in PPP1R12B tryptic phosphopeptide
645-659, pSpTQGVTLTDLQEAER, as well as the theoretical and
experimental m/z values for detected fragment ions. *Loss of H3PO4 (98
units) from the indicated fragment. #Loss of H2O (18 units). The ions
corresponding to b4, b5, y10, y11, and y12 are consistent with
phosphorylation on Ser645/Thr646. Figure S2. Tandem mass spectrum of
Ser760 phosphorylation in PPP1R12B tryptic phosphopeptide 755-773,
FSVPDpSESSETTTNTTTAK as well as the theoretical and experimental m/z
values for detected fragment ions. *Loss of H3PO4 (98 units) from the
indicated fragment. #Loss of H2O (18 units). The ions corresponding to
b5, b6, y11, y12, and y13 are consistent with phosphorylation on Ser760.
Figure S3. The representative image of the stained gel from which the
bands were excised.
Additionalf file 2: Table S1. PPP1R12B representative
unphosphorylated peptides peak area and retention time.
Additional file 3: Supplemental materials and methods.
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